News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2024

22 February, 2024 Year-End report January-December 2023 News English Regulatory MAR Report Interim Yearend IR Optional

2023

22 December, 2023 Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance News Corporate Information Staff change English IR Optional
19 December, 2023 Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today News Corporate Information Other Corporate Information English IR Optional
14 December, 2023 Egetis’ Investor Day on December 19: Agenda and Registration Details News Corporate Information Other Corporate Information English IR Optional
13 December, 2023 Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA News Corporate Information Other Corporate Information English IR Optional
1 December, 2023 Save the Date: Egetis to host Investor Day on December 19, 2023 News Corporate Information Other Corporate Information English IR Optional
10 November, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan News Corporate Action Other English Regulatory MAR IR Optional
8 November, 2023 Interim report Q3 2023 News English Regulatory MAR Report Interim Q3 IR Optional
7 November, 2023 Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs News Corporate Information Staff change English IR Optional
1 November, 2023 Egetis’ Nomination Committee for the 2024 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
27 October, 2023 Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
11 October, 2023 Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory LHFI IR Optional
9 October, 2023 Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency News Corporate Information Other Corporate Information English IR Optional
25 September, 2023 ReTRIACt trial design presented at the Annual Meeting of the European Society for Paediatric Endocrinology News Corporate Information Other Corporate Information English IR Optional
12 September, 2023 Egetis to participate at medical conferences to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
30 August, 2023 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional
22 August, 2023 Interim report Q2 2023 News English Regulatory MAR VPML Report Interim Q2 IR Optional
24 July, 2023 Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial News Corporate Information Other Corporate Information English IR Optional
28 June, 2023 Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
16 June, 2023 Board directors in Egetis Therapeutics acquire shares News Corporate Information Other Corporate Information English IR Optional
31 May, 2023 Board director in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
23 May, 2023 Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com